Low Back Pain-Pipeline Review, H1 2015

Low Back Pain-Pipeline Review, H1 2015

  • Products Id :- GMDHC6717IDB
  • |
  • Pages: 101
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Low Back Pain-Pipeline Review, H1 2015


Global Markets Direct's, 'Low Back Pain-Pipeline Review, H1 2015', provides an overview of the Low Back Pain's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Low Back Pain and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Low Back Pain

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Low Back Pain and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Low Back Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Low Back Pain pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Low Back Pain

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Low Back Pain pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Low Back Pain Overview 8

Therapeutics Development 9

Pipeline Products for Low Back Pain-Overview 9

Pipeline Products for Low Back Pain-Comparative Analysis 10

Low Back Pain-Therapeutics under Development by Companies 11

Low Back Pain-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Low Back Pain-Products under Development by Companies 16

Low Back Pain-Companies Involved in Therapeutics Development 18

Aestus Therapeutics, Inc. 18

Astellas Pharma Inc. 19

Collegium Pharmaceutical, Inc. 20

Eisai Co., Ltd. 21

Eli Lilly and Company 22

Frontier Biotechnologies Co., Ltd 23

Grunenthal GmbH 24

Ipsen S.A. 25

MEDRx Co., Ltd. 26

Merck & Co., Inc. 27

Mesoblast Limited 28

Nektar Therapeutics 29

Pacira Pharmaceuticals, Inc. 30

Paladin Labs Inc. 31

Pfizer Inc. 32

Stayble Therapeutics 33

Teikoku Pharma USA, Inc. 34

Low Back Pain-Therapeutics Assessment 35

Assessment by Monotherapy Products 35

Assessment by Combination Products 36

Assessment by Target 37

Assessment by Mechanism of Action 39

Assessment by Route of Administration 41

Assessment by Molecule Type 43

Drug Profiles 45

(acetaminophen + tramadol hydrochloride)-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

(diclofenac sodium + eperisone)-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

(etodolac + lidocaine)-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

(etoricoxib + tizanidine)-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

(oxycodone hydrochloride + naltrexone) ER-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

AB-001-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

abobotulinumtoxin A-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

ASP-7962-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Atx09-002-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

bupivacaine hydrochloride-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

cebranopadol-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Drug for Chronic Low Back Pain-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

duloxetine hydrochloride DR-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

eperisone SR-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

flurbiprofen sodium-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

MPC-06ID-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

NKTR-181-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

oxycodone hydrochloride ER-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

PF-06372865-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

Low Back Pain-Recent Pipeline Updates 75

Low Back Pain-Dormant Projects 89

Low Back Pain-Discontinued Products 91

Low Back Pain-Product Development Milestones 92

Featured News & Press Releases 92

Apr 07, 2015: Mesoblast Phase 3 Program For Degenerative Disc Disease To Include European Sites After Positive Meeting With European Medicines Agency 92

Feb 25, 2015: Nektar Announces Start of Phase 3 SUMMIT-07 Study of NKTR-181 in Patients with Chronic Low Back Pain 92

Jan 14, 2015: Mesoblast Reports Positive 24 Month Results in Phase 2 Trial for Chronic Low Back Pain and Initiation of Phase 3 Program at JP Morgan Healthcare Conference 93

Nov 13, 2014: Mesoblast's Phase 2 Trial Results In Chronic Low Back Pain Presented at North American Spine Society Annual Meeting 94

Apr 02, 2014: Collegium Pharmaceutical Announces Positive Topline Results of Clinical Study Evaluating the Effect of Crushing Oxycodone DETERx Compared with OxyContin 95

Mar 19, 2014: Collegium Pharmaceutical Announces Allowance of New Claims Covering DETERx, an Abuse-Deterrent, Extended-Release, Technology Platform 96

Feb 04, 2014: Collegium Pharmaceutical Announces Completion of Enrollment in Pivotal Phase 3 Clinical Study for Oxycodone DETERx, its Lead Abuse-Deterrent Development Program 96

Jan 23, 2014: Pfizer Reports Top-Line Results From ALO-02 Phase 3 Study 97

Oct 17, 2013: Collegium Pharmaceutical Announces Issuance of U.S. Patent and Allowance of New Claims Covering Oxycodone DETERx, an Abuse-Deterrent, Extended-Release Opioid Product 98

Apr 22, 2013: Mesoblast Reports Positive Interim Results In Phase II Trial Of Adult Stem Cells For Intervertebral Disc Repair 98

Appendix 100

Methodology 100

Coverage 100

Secondary Research 100

Primary Research 100

Expert Panel Validation 100

Contact Us 100

Disclaimer 101

List of Tables

Number of Products under Development for Low Back Pain, H1 2015 9

Number of Products under Development for Low Back Pain-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Late Stage Development, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Development, H1 2015 15

Products under Development by Companies, H1 2015 16

Products under Development by Companies, H1 2015 (Contd..1) 17

Low Back Pain-Pipeline by Aestus Therapeutics, Inc., H1 2015 18

Low Back Pain-Pipeline by Astellas Pharma Inc., H1 2015 19

Low Back Pain-Pipeline by Collegium Pharmaceutical, Inc., H1 2015 20

Low Back Pain-Pipeline by Eisai Co., Ltd., H1 2015 21

Low Back Pain-Pipeline by Eli Lilly and Company, H1 2015 22

Low Back Pain-Pipeline by Frontier Biotechnologies Co., Ltd, H1 2015 23

Low Back Pain-Pipeline by Grunenthal GmbH, H1 2015 24

Low Back Pain-Pipeline by Ipsen S.A., H1 2015 25

Low Back Pain-Pipeline by MEDRx Co., Ltd., H1 2015 26

Low Back Pain-Pipeline by Merck & Co., Inc., H1 2015 27

Low Back Pain-Pipeline by Mesoblast Limited, H1 2015 28

Low Back Pain-Pipeline by Nektar Therapeutics, H1 2015 29

Low Back Pain-Pipeline by Pacira Pharmaceuticals, Inc., H1 2015 30

Low Back Pain-Pipeline by Paladin Labs Inc., H1 2015 31

Low Back Pain-Pipeline by Pfizer Inc., H1 2015 32

Low Back Pain-Pipeline by Stayble Therapeutics, H1 2015 33

Low Back Pain-Pipeline by Teikoku Pharma USA, Inc., H1 2015 34

Assessment by Monotherapy Products, H1 2015 35

Assessment by Combination Products, H1 2015 36

Number of Products by Stage and Target, H1 2015 38

Number of Products by Stage and Mechanism of Action, H1 2015 40

Number of Products by Stage and Route of Administration, H1 2015 42

Number of Products by Stage and Molecule Type, H1 2015 44

Low Back Pain Therapeutics-Recent Pipeline Updates, H1 2015 75

Low Back Pain-Dormant Projects, H1 2015 89

Low Back Pain-Dormant Projects (Contd..1), H1 2015 90

Low Back Pain-Discontinued Products, H1 2015 91

List of Figures

Number of Products under Development for Low Back Pain, H1 2015 9

Number of Products under Development for Low Back Pain-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Assessment by Monotherapy Products, H1 2015 35

Assessment by Combination Products, H1 2015 36

Number of Products by Top 10 Targets, H1 2015 37

Number of Products by Stage and Top 10 Targets, H1 2015 37

Number of Products by Top 10 Mechanism of Actions, H1 2015 39

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 39

Number of Products by Top 10 Routes of Administration, H1 2015 41

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 42

Number of Products by Top 10 Molecule Types, H1 2015 43

Number of Products by Stage and Top 10 Molecule Types, H1 2015 44

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Aestus Therapeutics, Inc.

Astellas Pharma Inc.

Collegium Pharmaceutical, Inc.

Eisai Co., Ltd.

Eli Lilly and Company

Frontier Biotechnologies Co., Ltd

Grunenthal GmbH

Ipsen S.A.

MEDRx Co., Ltd.

Merck & Co., Inc.

Mesoblast Limited

Nektar Therapeutics

Pacira Pharmaceuticals, Inc.

Paladin Labs Inc.

Pfizer Inc.

Stayble Therapeutics

Teikoku Pharma USA, Inc.

Low Back Pain Therapeutic Products under Development, Key Players in Low Back Pain Therapeutics, Low Back Pain Pipeline Overview, Low Back Pain Pipeline, Low Back Pain Pipeline Assessment

select a license

Single User License
USD 2000 INR 132420
Site License
USD 4000 INR 264840
Corporate User License
USD 6000 INR 397260



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com